Sign In
Last checked at 
22 Jul 2022 07:00
22 July 2022
Cambridge Cognition Holdings Plc
("Cambridge Cognition", the "Company" or the "Group")
Director/PDMR Share Purchases
Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, was informed on 21 July 2022 of the following purchases of the Company's ordinary shares by Directors and PDMRs of the Company.
The purchases made on 21 July 2022 are detailed in the table below:
Director/PDMR | No. of Ordinary Shares purchased | Purchase price per Ordinary Share | Total no. of Ordinary Shares held | Percentage ownership of total issued share capital |
Matthew Stork | 22,950 | £1.13 | 147,950 | 0.47% |
Stephen Symonds | 22,950 | £1.13 | 22,950 | 0.07% |
Further information on the purchases is contained in the disclosure tables below.
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
For further information, please contact:
Cambridge Cognition Holdings Plc | Tel: 01223 810 700 |
Matthew Stork, Chief Executive Officer | press@camcog.com |
Stephen Symonds, Chief Financial Officer | |
Panmure Gordon (UK) Ltd (NOMAD and Joint Broker) |
Tel: 020 78862500 |
Freddy Crossley / Emma Earl / Mark Rodgers | (Corporate Advisory) |
Rupert Dearden | (Corporate Broking) |
Dowgate Capital Limited (Joint Broker) | Tel: 020 3903 7715 |
David Poutney / James Serjeant | |
IFC Advisory Ltd (Financial PR and IR) | Tel: 020 3934 6630 |
Tim Metcalfe / Graham Herring / Zach Cohen | cog@investor-focus.co.uk |
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Matthew Stork | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b)
| Initial notification /Amendment | Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Cambridge Cognition Holdings Plc | ||||
b) | LEI | 213800SZKDIN122EPA96 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of 0.01p each
GB00B8DV9647 | ||||
b) | Nature of the transaction | Purchase of Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | 22,950 £1.13 | ||||
e) | Date of the transaction | 21 July 2022 | ||||
f) | Place of the transaction | London Stock Exchange
| ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Stephen Symonds | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer | ||||
b)
| Initial notification /Amendment | Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Cambridge Cognition Holdings Plc | ||||
b) | LEI | 213800SZKDIN122EPA96 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of 0.01p each
GB00B8DV9647 | ||||
b) | Nature of the transaction | Purchase of Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | 22,950 £1.13 | ||||
e) | Date of the transaction | 21 July 2022 | ||||
f) | Place of the transaction | London Stock Exchange
| ||||
Follow the stocks
